| CEO Name | Paul McKenzie |
| Nationality | Australia |
| Net Worth Estimation | $15 million |
Paul McKenzie, current CEO of CSL Limited, has an estimated net worth of around $15 million USD, primarily derived from executive compensation, performance-based bonuses, and substantial equity holdings in CSL Limited. This valuation reflects both his career progression within the pharmaceutical industry and the overall market value of CSL Limited shares granted to him as part of his remuneration package.
Paul McKenzie, CEO of CSL Limited, has an estimated net worth of $15,000,000, which is 1.03% of the maximum and 50% above the minimum CEO net worth for the pharmaceutical industry. His net worth places him at the lower end of the typical range ($10,000,000-$500,000,000) for CEOs in this sector.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Paul McKenzie Performance in CSL Limited
Paul McKenzie, CEO of CSL Limited, demonstrates strategic leadership focused on innovation and global expansion in the biopharmaceutical sector. His decision-making prioritizes research and development investments, driving CSL's competitive edge and consistent revenue growth. Under his tenure, CSL has strengthened its market position, enhanced operational efficiency, and delivered sustained shareholder value.
Latest News
CSL Limited Reports Strong FY2025 Results Amid Major Restructuring
CSL Limited posted a net profit after tax of $3.3 billion for FY2025, a 14% increase at constant currency, driven by strong demand for plasma therapies. CEO Paul McKenzie announced a major restructuring, including a planned spin-off of Seqirus and workforce reductions, while acknowledging future earnings growth may shift to high single digits.
Source: http://www.cslbehring.de/en-us/news/2025/jahresergebnisse-2025